<SEC-DOCUMENT>0001104659-20-138093.txt : 20201221
<SEC-HEADER>0001104659-20-138093.hdr.sgml : 20201221
<ACCEPTANCE-DATETIME>20201221164631
ACCESSION NUMBER:		0001104659-20-138093
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20201217
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201221
DATE AS OF CHANGE:		20201221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		201404828

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2039008d3_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported): December 17, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>0-50626</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>91-1707622</B></FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(State or other jurisdiction<BR>
of incorporation)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Commission File Number)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(IRS Employer<BR>
Identification No.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>200 Connell Drive, Suite 1500<BR>
Berkeley Heights, NJ 07922<BR>
(Address of principal executive offices and zip code) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&#8217;s telephone number,
including area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Former name or former address, if changed
since last report.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(<I>see </I>General Instruction A.2. below): </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Securities registered pursuant to Section
12(b) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; width: 32%"><FONT STYLE="font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 32%"><FONT STYLE="font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 32%"><FONT STYLE="font-size: 10pt"><B>Name of each exchange on which registered </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Common Stock, par value $0.001 per share</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">CYCC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">The Nasdaq Stock Market LLC</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Preferred Stock, $0.001 par value</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">CYCCP</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">The Nasdaq Stock Market LLC</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B>Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B>If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <B>Item 5.02</B> <B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Effective December 17, 2020, the Board of
Directors (the &ldquo;Board&rdquo;) of the Cyclacel Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) appointed Brian Schwartz,
M.D. to serve as a Class 2 Director until the 2023 annual meeting of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are no arrangements or understandings
between Dr. Schwartz and any other person pursuant to which Dr. Schwartz was appointed as a director. There are no transactions
to which the Company is a party and in which Dr. Schwartz has a material interest that is required to be disclosed under Item 404(a)
of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Dr. Schwartz has not previously held any
positions with the Company and has no family relations with any directors or executive officers of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On December 17, 2020, the Board granted,
under and pursuant to the terms of the Company&#8217;s 2018 Equity Incentive Plan, to Dr. Schwartz an option to purchase up to
5,200 shares of the Company&#8217;s common stock at an exercise price of $4.13 per share for his services as a non-executive director
of the Company, all of such options to vest on the first anniversary of the date of grant. The option expires on December 17, 2030.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, Dr. Schwartz is entitled to
receive an annual fee of $45,000 for his services as a non-executive director of the Company. Dr. Schwartz will also be reimbursed
for certain customary business expenses in connection with attending the Board meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Dr. Schwartz has a successful track record
in oncology drug development at several biopharmaceutical companies. He most recently served as Chief Medical Officer of ArQule
Inc., a biopharmaceutical company acquired by Merck &amp; Co. for $2.7 billion in early 2020. During his 11 years at ArQule, he
served as a senior member of the management team and managed interdisciplinary teams that advanced preclinical and clinical drug
development programs in oncology and rare diseases. Prior to ArQule, he served as Chief Medical Officer and Senior Vice President,
Clinical and Regulatory Affairs at Ziopharm Oncology, Inc., where he built and led clinical, regulatory, and quality assurance
teams developing novel cancer therapies. Earlier in his career, he held several positions at Bayer Healthcare and Leo Laboratories.
At Bayer, he was most recently Medical Director, US Oncology and previously Global Clinical Leader responsible for the development
and approval of sorafenib (Nexavar&reg;) in all major markets. He has extensive regulatory experience working with the US FDA,
the European Medicines Agency (EMA), and other competent health authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Dr. Schwartz currently serves on the Board
of Directors of Enlivex Therapeutics Limited, LifeSci Acquisition Corp. and Mereo BioPharma Group plc. He earned his medical degree
and did his residency at the University of Pretoria, South Africa, did his fellowship at the University of Toronto and practiced
medicine before his career in the biopharmaceutical industry.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Attached as Exhibit 99.1 is a copy of a
press release of the Company, dated December 21, 2020, announcing the election of Dr. Schwartz to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Item 9.01: Financial
Statements and Exhibits.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Exhibits.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit Number</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="tm2039008d3_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="tm2039008d3_ex99-1.htm" STYLE="-sec-extract: exhibit">Press
    release announcing the election of Brian Schwartz, M.D., dated December 21, 2020.</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 171pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Paul McBarron</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Paul McBarron</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President&#8212;Finance, Chief Financial Officer and Chief Operating Officer</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: December 21, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2039008d3_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><IMG SRC="tm2039008d3_ex99-1img01.jpg" ALT=""></TD>
    <TD STYLE="vertical-align: middle; text-align: right; width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel Pharmaceuticals, Inc</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="tm2039008d3_ex99-1img02.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Cyclacel
Pharmaceuticals aNNOUncES </B></FONT><B>THAT BRIAN SCHWARTZ, M.D. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>WAS
ELECTEd TO ITS BOARD OF DIRECTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><I>-F</I></FONT><I>ormer
CMO &amp; Head of R&amp;D of ArQule joins the Board-</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 174.25pt; text-align: center; text-indent: -2.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>BERKELEY HEIGHTS, NJ, December 21,
2020</B> - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &quot;Cyclacel&quot; or the &quot;Company&quot;), a biopharmaceutical
company developing innovative medicines based on cancer cell biology, today announced <FONT STYLE="color: #2E2E2E">the election
of&nbsp;Brian Schwartz, M.D., to its Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #2E2E2E">&quot;We are very pleased
to have Brian join the Board of Directors of Cyclacel. His extensive clinical and product development experience further adds to
the strength of our Board and will support management&rsquo;s efforts to build shareholder value,&quot; said Christopher Henney,
Ph.D., Chairman of the Board of Cyclacel. &ldquo;Brian&rsquo;s experience in all development stages of innovative medicines for
cancer will be very valuable as we advance our business strategy.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #2E2E2E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ldquo;I am excited to join the Board
at an important moment in the Company&rsquo;s history,&rdquo; said Dr. Schwartz. &ldquo;After evaluating the scientific and clinical
merits of Cyclacel&rsquo;s medicines, I am enthusiastic of the prospects of fadraciclib and CYC140. These two internally discovered
molecules have competitive product profiles and address oncology indications with large unmet medical needs. The clinical development
plans and Cyclacel&rsquo;s experienced management team provide a strong basis for success in the Company&rsquo;s programs.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Dr Schwartz has wide-ranging experience
as a drug development expert in pharmaceutical and biotechnology industries primarily in oncology, hematology, and rare diseases.
During the past decade he has served as Senior Vice President, Head of Research &amp; Development and Chief Medical Officer of
ArQule Inc., which was&nbsp;acquired for $2.7bn by Merck &amp; Co. in 2020. Prior to ArQule, Dr. Schwartz was CMO at Ziopharm,
having previously held several senior leadership roles at Bayer and LEO Pharma. He is currently a Board Member of LifeSci Acquisition
Corp, Mereo Biopharma and Enlivex. In addition, he serves as an advisor, SAB member and independent consultant for numerous biotech
and investment companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">He received his medical degree from
the University of Pretoria, South Africa, completed a fellowship at the University of Toronto, Canada and practiced medicine prior
to his career in the biopharmaceutical industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical
company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional
regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, in solid tumors and hematological malignancies. The anti-mitotic
program is evaluating CYC140, a PLK1 inhibitor, in advanced cancers. Cyclacel's strategy is to build a diversified biopharmaceutical
business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information,
please visit <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>www.cyclacel.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 8pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><FONT STYLE="font-family: Wingdings; font-size: 8pt">&thorn;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;200
Connell Drive, Suite 1500, Berkeley Heights, NJ 07922, USA Tel +1 908 517 7330 Fax +1 866 271 3466</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Wingdings; font-size: 8pt">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;1&#8239;James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382 206 067</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 8pt"><U>www.cyclacel.com
</U>&ndash; <U>info@cyclacel.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This news release contains certain
forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from
historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements
include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates,
the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and
plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product
candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale
or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates,
the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on
collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to
consider statements that include the words &quot;may,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot;
&quot;believes,&quot; &quot;estimates,&quot; &quot;projects,&quot; &quot;potential,&quot; &quot;expects,&quot; &quot;plans,&quot;
&quot;anticipates,&quot; &quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot; &quot;designed,&quot; &quot;goal,&quot;
or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description
of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic
and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements
are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as
a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #2E2E2E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #2E2E2E">Company:&nbsp;Paul McBarron, (908)
517-7330,&nbsp;</FONT><U>pmcbarron@cyclacel.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #2E2E2E">Investor Relations:&nbsp;Russo
Partners LLC, Jason Assad</FONT>, (646) 218-4604, <U>jason.assad@russopartnersllc.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&copy; Copyright 2020 Cyclacel Pharmaceuticals, Inc. All Rights
Reserved. The Cyclacel logo and Cyclacel&reg; are trademarks of Cyclacel Pharmaceuticals, Inc.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2039008d3_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2039008d3_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !& +8# 2(  A$! Q$!_\0
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M"M[_ !A^*&COXZ\9^*_VEK;]F/Q5X/TK3?$7@;XM_'#3=<U_Q/I7BSQPNO\
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MUP?'K_@KK+H_F_\ "2ZQ\*_@^GA $\+'#\"?B!;:0%'JOB%I<<Y#(./3TO\
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M=7<@&6*>)W5@2-B*HC\MU+C^:_X.?L]?\%&?^")7Q4^.?@[]DO\ 993]OO\
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M-Y/ _@/3S&7_ +;U[^P==>=]%CP%W(7+$KY:S8#4 ?$O_!(+_E-7_P '"_\
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7 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2039008d3_ex99-1img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2039008d3_ex99-1img02.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  = CL# 2(  A$! Q$!_\0
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M702MK-O6<1V^0Y>=596;]0+=UE"2KNVS*ES'N1DPCIA=RN%=)2K R*XR"<$
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M,NO&J>5XMN/#>CS>(U1!'&=7>RC-Z#&"=D@FR9>B,_\ JRRX( .Z=LJVT!F
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MYF2,( !]T?=4K&HC ! "!$4#KCDGC.#V/B/_  I2\/#?&?XU$=Q_PDV@<_\
MEJ>M)_PI*X_Z+)\:?_"GT'_YE* /<6&5(QG./3CD?-SQ\OWO7CCG%0-"LJE)
M8_-0;59)EBDCD*D,)0C%@"'&X9P<CA<@,/%?^%)7'_19/C3_ .%/H/\ \RE'
M_"DKC_HLGQI_\*?0?_F4H ]L1"""QDPA^4,(]I&TK^[6/[H&<989 R.021-G
MZ_D?\*\-_P"%)7(Y7XR_&D'L?^$FT#C_ ,M3TI?^%*7AX;XS_&HCN/\ A)M
MY_\ +4]: /<J*\,_X4E<?]%D^-/_ (4^@_\ S*4?\*2N/^BR?&G_ ,*?0?\
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M0N%C0+@ !@.!QS[9KQ/_ (4E<?\ 19/C3_X4^@__ #*4?\*2N/\ HLGQI_\
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M88(Z 'C]*\._X4E<?]%D^-/_ (4^@_\ S*4?\*2N/^BR?&G_ ,*?0?\ YE*
M/<F&01@'. 0W(*DC</J5SCMG&>*JHLI!S$$+HKL66(X>4/YL9$;8<QLL1D8Y
M613A&9AQXO\ \*2N/^BR?&G_ ,*?0?\ YE*/^%)7'_19/C3_ .%/H/\ \RE
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M@ , 1U5<?*2<$>)+\%+PL WQG^-1'.1_PDV@#/!_ZE3UJ7_A25Q_T63XT_\
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&X!- '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
